4.3 Review

COVID-19: Using high-throughput flow cytometry to dissect clinical heterogeneity

Journal

CYTOMETRY PART A
Volume 103, Issue 2, Pages 117-126

Publisher

WILEY
DOI: 10.1002/cyto.a.24516

Keywords

High-throughput flow cytometry; COVID-19; cancer; cell cycle; Ki-67; DNA dye

Ask authors/readers for more resources

This article discusses the use of high-content flow cytometric methodology to rapidly provide meaningful biological data in COVID-19 studies. High-throughput flow cytometry helps identify immune signatures and investigate the impact of SARS-CoV-2 exposure on cancer patients. Integration of flow cytometry data with other metrics can differentiate the immune profiles of COVID-19 patients from healthy donors and non-COVID respiratory infection patients.
Here we consider how high-content flow cytometric methodology at appropriate scale and throughput rapidly provided meaningful biological data in our recent studies of COVID-19, which we discuss in the context of other similar investigations. In our work, high-throughput flow cytometry was instrumental to identify a consensus immune signature in COVID-19 patients, and to investigate the impact of SARS-CoV-2 exposure on patients with either solid or hematological cancers. We provide here some examples of our 'holistic' approach, in which flow cytometry data generated by lymphocyte and myelomonocyte panels were integrated with other analytical metrics, including SARS-CoV-2-specific serum antibody titers, plasma cytokine/chemokine levels, and in-depth clinical annotation. We report how selective differences between T cell subsets were revealed by a newly described flow cytometric T-DS assay to distinguish actively cycling T cells in the peripheral blood. By such approaches, our and others' high-content flow cytometry studies collectively identified overt abnormalities and subtle but critical changes that discriminate the immuno-signature of COVID-19 patients from those of healthy donors and patients with non-COVID respiratory infections. Thereby, these studies offered several meaningful biomarkers of COVID-19 severity that have the potential to improve the management of patients and of hospital resources. In sum, flow cytometry provides an important means for rapidly obtaining data that can guide clinical decision-making without requiring highly expensive, sophisticated equipment, and/or -omics capabilities. We consider how this approach might be further developed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available